This segment focuses on the research, development, and clinical trials of novel therapeutics for rare hematologic diseases, including sickle cell disease and other hemoglobinopathies. Research and development activities include identifying and validating drug targets, designing and synthesizing drug candidates, and conducting preclinical and clinical studies. The company utilizes various technologies and methodologies, such as small molecule drug discovery and development. The patient impact is significant, as these therapies aim to improve the quality of life and survival rates for patients with rare and often life-threatening blood disorders. Forma Therapeutics' market positioning is as a clinical-stage biopharmaceutical company with a focus on unmet medical needs in rare diseases. Future opportunities include expanding the pipeline with additional drug candidates and seeking regulatory approvals for commercialization. Clinical trials are a core component of this segment, with regulatory compliance and patient safety being paramount.

This segment is dedicated to the development of innovative therapies for various cancers, with a primary focus on metastatic castration-resistant prostate cancer and cancers with isocitrate dehydrogenase 1 gene mutations. Research and development efforts involve identifying and validating cancer targets, designing and synthesizing drug candidates, and conducting preclinical and clinical trials. The company employs technologies such as small molecule inhibitors. The therapeutic areas covered include prostate cancer and acute myeloid leukemia. The patient impact is aimed at improving outcomes and extending the lives of cancer patients. Forma Therapeutics' market positioning is as a clinical-stage biopharmaceutical company with a focus on unmet medical needs in oncology. Future opportunities include expanding the oncology pipeline and seeking regulatory approvals. Clinical trials are a key aspect of this segment, with regulatory compliance and patient safety being critical.